Suven Life Sciences secures Product Patents in Australia, Singapore

16 Jan 2019 Evaluate

Suven Life Sciences (Suven) has secured one product patent from Australia and one product patent from Singapore corresponding to the New Chemical Entities for the treatment of disorders associated with Neurodegenerative diseases and patents are valid through 2036.

The granted claims of the patents include the class of selective 5-HT4 and M1 PAM compounds respectively and are being developed as therapeutic agents for neurodegenerative disorders such as for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia etc.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies using GPCR targets.

Suven Life Sciences Share Price

167.15 0.30 (0.18%)
01-Jan-2026 09:35 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1710.70
Dr. Reddys Lab 1253.15
Cipla 1500.60
Zydus Lifesciences 910.00
Lupin 2095.00
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×